Goulburn, Dar and Li believe a shift is underway in biotech.
The three friends, who have helped build new companies with their respective firms for about a decade, are convinced the search for new drugs is becoming increasingly digitized. Artificial intelligence and other digital technologies are now more useful in drug development. The shift is birthing new types of biotechs built around high-powered computing software and, unlike previously, staffed with as many computer scientists as biologists.
